Rivus Pharmaceuticals announced new Phase IIa HuMAIN study data for HU6, its investigational treatment for obesity-related ...

The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will ...

AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has ...

Family-controlled Italian drugmaker Chiesi Group yesterday celebrated the operational launch of its Biotech Center of ...

Kezar Life Sciences saw its share tumble more than 42% to 40.77 yesterday, after it revealed it was voluntarily pausing ...

Germany-headquartered CNS drug specialist Neuraxpharm Group today announced the launch of Neuraxpharm Middle East to cover ...

Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized ...

A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for ...

India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked ...

Cambridge, USA-based Prime Medicine saw its shares rocket more than 38% to $4.78 today, as it revealed a strategic research ...

Grünenthal has appointed Jan Adams as its new chief commercial officer, effective October 1. Dr. Adams, currently the chief ...

US RNAi therapeutics company Alnylam Pharmaceuticals has released two new data sets from the HELIOS-B Phase III study of ...